On the 22nd, Energenesis Biomedical announced that it has successfully integrated AI technology to tap into the emerging market of drug repurposing. The company is currently targeting high-selling drugs with patents set to expire within the next ten years, aiming to accelerate the discovery of new indications. These candidates are undergoing cell and animal model validation, alongside patent and intellectual property planning for future licensing. Two promising new indications are already under development. To further advance its AI-driven drug development model, Energenesis made its debut at this year’s COMPUTEX Taipei, drawing significant attention with its strategic approach to AI in drug repurposing.

General Manager Chen, Han-Min noted that the company has successfully consolidated a large-scale knowledge base into the Llama-3 model and continues to expand its proprietary database. Several promising new indications have already been identified, and the company plans to push forward with commercial collaborations this year to accelerate the application of AI in repurposing off-patent drugs. Chen highlighted that AI has the potential to overcome the long development timelines, high costs, and low success rates associated with traditional new drug development. While AI-designed new chemical entities may raise the success rate to 15–20% through optimized molecular design, the approach still faces data and technical challenges. In contrast, AI-driven drug repurposing benefits from existing safety data, potentially increasing success rates to around 40%, while significantly reducing development time and costs.

Energenesis is focusing on blockbuster drugs with strong terminal sales and patents expiring within the next decade, aiming to discover new therapeutic uses. The goal is to identify ten high-potential cases per year, with at least three progressing into validation and IP planning. Licensing targets will primarily be original manufacturers seeking to extend the commercial lifecycle of their products. Licensing fees are projected to range from USD 1 million to 3 million, with subsequent revenue sharing once the new indications receive regulatory approval.

Resource: 華安應用AI 攻老藥新用藍海